Two Sigma Investments LP Has $18.25 Million Position in TG Therapeutics, Inc. (NASDAQ:TGTX)

Two Sigma Investments LP cut its holdings in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 43.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 606,208 shares of the biopharmaceutical company's stock after selling 456,652 shares during the period. Two Sigma Investments LP owned approximately 0.39% of TG Therapeutics worth $18,247,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Arizona State Retirement System lifted its position in TG Therapeutics by 0.9% in the fourth quarter. Arizona State Retirement System now owns 42,639 shares of the biopharmaceutical company's stock worth $1,283,000 after purchasing an additional 364 shares during the period. Blue Trust Inc. lifted its position in TG Therapeutics by 24.5% in the fourth quarter. Blue Trust Inc. now owns 1,887 shares of the biopharmaceutical company's stock worth $57,000 after purchasing an additional 371 shares during the period. Summit Investment Advisors Inc. lifted its position in TG Therapeutics by 3.3% in the fourth quarter. Summit Investment Advisors Inc. now owns 14,606 shares of the biopharmaceutical company's stock worth $440,000 after purchasing an additional 463 shares during the period. Daymark Wealth Partners LLC lifted its position in TG Therapeutics by 1.7% in the fourth quarter. Daymark Wealth Partners LLC now owns 41,500 shares of the biopharmaceutical company's stock worth $1,249,000 after purchasing an additional 689 shares during the period. Finally, New York State Teachers Retirement System lifted its position in TG Therapeutics by 1.9% in the fourth quarter. New York State Teachers Retirement System now owns 43,764 shares of the biopharmaceutical company's stock worth $1,317,000 after purchasing an additional 837 shares during the period. 58.58% of the stock is currently owned by institutional investors and hedge funds.

TG Therapeutics Price Performance

Shares of NASDAQ TGTX traded up $0.10 during trading on Wednesday, hitting $35.34. The company had a trading volume of 354,910 shares, compared to its average volume of 2,972,785. The company has a market cap of $5.61 billion, a P/E ratio of -352.91 and a beta of 2.21. TG Therapeutics, Inc. has a 52 week low of $15.16 and a 52 week high of $46.48. The business's 50-day moving average is $37.84 and its 200 day moving average is $34.36. The company has a debt-to-equity ratio of 1.27, a quick ratio of 3.91 and a current ratio of 4.59.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last announced its earnings results on Wednesday, May 7th. The biopharmaceutical company reported $0.03 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.19 by ($0.16). TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. The firm had revenue of $120.86 million for the quarter, compared to analyst estimates of $117.07 million. During the same period last year, the firm earned ($0.07) earnings per share. TG Therapeutics's revenue for the quarter was up 90.4% compared to the same quarter last year. Equities research analysts predict that TG Therapeutics, Inc. will post 0.08 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the company. Wall Street Zen upgraded TG Therapeutics from a "sell" rating to a "hold" rating in a research report on Tuesday, March 4th. HC Wainwright reaffirmed a "buy" rating and issued a $55.00 price target on shares of TG Therapeutics in a report on Tuesday, March 4th. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $40.80.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.